{"brief_title": "Study Evaluating TMI-005 in Active Rheumatoid Arthritis", "brief_summary": "The primary objective of this clinical research study is to compare the efficacy and the safety of 3 dose levels of oral TMI-005 in comparison with placebo in subjects with active Rheumatoid Arthritis (RA) who have been receiving stable doses of Methotrexate (MTX).", "condition": "Rheumatoid Arthritis", "intervention_type": "Drug", "intervention_name": "TMI-005", "criteria": "Inclusion Criteria: - Meet American College of Rheumatology (ACR) criteria for RA - Have active RA - Disease duration of at least 6 months - Disease onset at > 16 years of age. Exclusion Criteria: - Any prior use of anti-TNF alpha biologics, rituximab, receipt of anti-CD4 or diphtheria interleukin-2 fusion protein or other immunosuppressive biologics (except for anakinra) - Largely or wholly incapacitated with the subject bedridden or confined to a wheelchair, permitting limited or no self-care - Pregnant or breastfeeding women or women planning to become pregnant during the study or within 12 weeks after the last dose of test article", "gender": "All", "minimum_age": "18 Years", "maximum_age": "75 Years", "healthy_volunteers": "No", "id": "NCT00095342.xml"}